Pomalidomide Capsule
Product Images NDC 31722-772

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Pomalidomide (NDC 31722-772). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1mg21countcontainerlabel (1mg21countcontainerlabel)

Pomalidomide Capsules 1 mg label from Camber Pharmaceuticals, Inc. The label includes a warning about potential human birth defects, storage instructions, a barcode, and manufacturer details for Hetero Labs Limited in India. The package contains 21 capsules.*

FDA Label Image

2mg21countcontainerlabel (2mg21countcontainerlabel)

Pomalidomide Capsules 2 mg oral capsules label from Camber Pharmaceuticals, Inc. The label includes a warning about potential human birth defects, pharmacist dispensing instructions, storage conditions (20°C to 25°C), and manufacturer information for Hetero Labs Limited in India. The package contains 21 capsules and displays the NDC 31722-771-21.*

FDA Label Image

3mg21countcontainerlabel (3mg21countcontainerlabel)

Pomalidomide Capsules 3 mg oral capsules label by Camber Pharmaceuticals, Inc. The label includes a warning about potential human birth defects and storage instructions. The NDC is 31722-772-21. The package contains 21 capsules. Manufacturer information is listed as Hetero Labs Limited in India, with Camber Pharmaceuticals noted as the labeler in Piscataway, NJ.*

FDA Label Image

4mg21countcontainerlabel (4mg21countcontainerlabel)

Pomalidomide Capsules 4 mg oral dose packaging label by Camber Pharmaceuticals, Inc. The label includes warnings about potential birth defects, storage instructions, pharmacist dispensing notes, and the quantity of 21 capsules. It also shows the manufacturing information by Hetero Labs Limited in India and provides a U.S. contact number.*

FDA Label Image

Camberlogo (Camberlogo)

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical structure of pomalidomide. This diagram depicts the molecular structure of the active ingredient pomalidomide, showing its ring systems and functional groups as part of the drug's chemical identity.*

FDA Label Image

Figure1 (Figure1)

A Kaplan-Meier survival curve graph showing progression free survival over months. Two treatment groups are compared: HD-DEX (solid line) and POM+LD-DEX (dashed line). The y-axis represents the proportion of subjects; the x-axis represents progression free survival in months. A table below shows the number of subjects at risk for each time point for both groups.*

FDA Label Image

Figure2 (Figure2)

Kaplan-Meier curve illustrating overall survival for the intent-to-treat population comparing two treatment groups: HD-DEX and POM+LD-DEX. The graph plots the proportion of subjects surviving over a period of months, with survival curves for each group and a risk table showing the number of subjects at risk over time.*

FDA Label Image

Table3 (Table3)

A data table summarizing adverse reactions in patients treated with Pomalidomide versus Pomalidomide plus low-dose Dexamethasone. It details incidence percentages of various adverse reactions by body system, comparing all reactions ≥10% and Grade 3 or 4 reactions ≥5% in either treatment arm, covering blood disorders, gastrointestinal, musculoskeletal, infections, metabolism, respiratory, nervous system, skin, psychiatric, renal, and other categories.*

FDA Label Image

Table4 (Table4)

Table detailing adverse reactions in patients treated with pomalidomide versus low-dose dexamethasone. It includes body system classifications and the percentage occurrence of various side effects such as neutropenia, fatigue, pyrexia, infections, gastrointestinal, musculoskeletal, respiratory, neurological, metabolic, skin, and other disorders, with data stratified by severity and dose received.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.